english.prescrire.org > Spotlight > Archives : 2016 > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2016 : 1 | 30 | 60

In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants

FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable.
Full text available for free download.

Summary

  • Adalimumab (Humira°, Abbvie), a TNF-alpha antagonist authorised for the treatment of various paediatric disorders, has been approved for use in children with severe plaque psoriasis in whom local treatment or phototherapy has failed.
     
  • Overall, compared to methotrexate, adalimumab seemed slightly more effective on psoriatic lesions, but relapses after treatment withdrawal were more frequent.
     
  • Because of its potentially serious adverse effects, including a risk of infections and cancer, adalimumab, like other immunosuppressants, should only be considered for children with very debilitating plaque psoriasis.

Full text available for free download.

 ©Prescrire 1 July 2016

"Adalimumab (Humira°) and plaque psoriasis in children" Prescrire Int 2016; 25 (173): 176. (Pdf, free)
Download the full review
Pdf, free